Mizuho Securities upgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Neutral to Buy with a price target of $193.00 (from $137.00) on Xyrem Settlements.

Analyst Irina Koffler commented, "Jazz's announcement of its late 2025 Xyrem settlements was the upgrade signal we were looking for. We modeled Xyrem exclusivity through 2025 and lowered the WACC in our DCF model from 13% to 12% which led to our Buy rating and $193 PT (up from Neutral and $137, previously)."

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $147.82 yesterday.